IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

Conditions: Arrhythmogenic Right Ventricular Dysplasia; Arrhythmogenic Left Ventricular Cardiomyopathy; Arrhythmogenic Right Ventricular Cardiomyopathy 1; Arrhythmogenic Cardiomyopathy
Interventions: Biological: IC14
Sponsors: Implicit Bioscience
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 24, 2024Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments